Experimental cancer treatments

ImmVira and Shanghai Pharma Announce Clinical Collaboration and License Agreement for Commercialization of Novel Intratumoral Oncolytic Virus Immunotherapies

Retrieved on: 
Thursday, August 6, 2020
Virotherapy, Clinical medicine, Medicine, Experimental cancer treatments, Oncolytic virus, Health care, Immunotherapy, Pharmaceutical industry in China, Oncolytic adenovirus

SHENZHEN and SHANGHAI, August 6, 2020 /PRNewswire/ -- ImmVira Group Company and Shanghai Pharmaceuticals Holding Co., Ltd today announced a clinical collaboration and exclusive license agreement for ImmVira's MVR-T3011 intratumoral oncolytic virus program for the commercialization of novel immunotherapies to treat solid malignant tumors.

Key Points: 
  • SHENZHEN and SHANGHAI, August 6, 2020 /PRNewswire/ -- ImmVira Group Company and Shanghai Pharmaceuticals Holding Co., Ltd today announced a clinical collaboration and exclusive license agreement for ImmVira's MVR-T3011 intratumoral oncolytic virus program for the commercialization of novel immunotherapies to treat solid malignant tumors.
  • ImmVira's MVR-T3011 oncolytic virus program has innovated with a genetically engineered oncolytic herpes simplex virus-1 (oHSV-1) to enhance the known oncolytic effects of oHSV-1.
  • As part of the agreement, Shanghai Pharma will receive an exclusive license and gain access to ImmVira's MVR-T3011 virus for clinical development, manufacturing and commercialization within certain fields of use in mainland China, Hong Kong, Macau and Taiwan (the Greater China region).
  • ImmVira and Shanghai Pharma will collaborate on clinical trials in China with exclusive commercial rights for intratumoral therapies developed under the agreement assigned to Shanghai Pharma for the Greater China region.

Replimune to Present at Two Upcoming Investor Conferences

Retrieved on: 
Tuesday, August 4, 2020
Oncolytic virus, Wedbush Securities, Cancer immunotherapy, Clinical medicine, Experimental cancer treatments, Medicine, Medical specialties, Biotechnology, Virotherapy

WOBURN, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL) a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences.

Key Points: 
  • WOBURN, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL) a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences.
  • A simultaneous webcast of the presentation from the 2020 Wedbush PacGrow Healthcare Virtual Conference will be available in the Investors section of Replimunes website at www.replimune.com.
  • Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer.
  • Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action.For more information, please visit www.replimune.com .

Valo Therapeutics Appoints Industry Veteran Paul Higham as CEO

Retrieved on: 
Monday, August 3, 2020
Virotherapy, Cancer immunotherapy, Oncolytic virus, Clinical medicine, Medicine, Experimental cancer treatments, Medical specialties, Adenoviridae, Biotechnology

OXFORD, England and HELSINKI, Aug. 3, 2020 /PRNewswire/ --Valo Therapeutics Limited (Valo Tx), an immuno-oncology company developing targeted therapeutics using tumor antigen-coated oncolytic viruses, today announced it had appointed industry veteran Paul G Higham as Chief Executive Officer (CEO), to lead the company through a Series A round and take its PeptiCRAd platform into first-in-human cancer clinical trials.

Key Points: 
  • OXFORD, England and HELSINKI, Aug. 3, 2020 /PRNewswire/ --Valo Therapeutics Limited (Valo Tx), an immuno-oncology company developing targeted therapeutics using tumor antigen-coated oncolytic viruses, today announced it had appointed industry veteran Paul G Higham as Chief Executive Officer (CEO), to lead the company through a Series A round and take its PeptiCRAd platform into first-in-human cancer clinical trials.
  • Paul G Higham, CEO of Valo Tx, said, "Despite the tremendous progress that has been made, there is still huge potential for immuno-oncology to further improve outcomes for patients.
  • Valo Therapeutics (Helsinki and Oxford) is animmuno-oncology company that is developing tumor antigen-coated oncolytic viruses as anti-cancer therapeutics stimulating specific anti-tumor T-cell responses.
  • Paul G Higham is a healthcare industry veteran with extensive leadership experience in large pharmaceutical and biotech companies.

Valo Therapeutics Appoints Industry Veteran Paul Higham as CEO

Retrieved on: 
Monday, August 3, 2020
Cancer immunotherapy, Oncolytic virus, Clinical medicine, Virotherapy, Medical specialties, Medicine, Adenoviridae, Experimental cancer treatments, Biotechnology

Previously CEO at immuno-oncology companies Glycotope and Immatics, with senior positions at Ark Therapeutics, GSK and Bayer

Key Points: 
  • Previously CEO at immuno-oncology companies Glycotope and Immatics, with senior positions at Ark Therapeutics, GSK and Bayer
    OXFORD, England and HELSINKI, Aug. 3, 2020 /PRNewswire/ --Valo Therapeutics Limited (Valo Tx), an immuno-oncology company developing targeted therapeutics using tumor antigen-coated oncolytic viruses, today announced it had appointed industry veteran Paul G Higham as Chief Executive Officer (CEO), to lead the company through a Series A round and take its PeptiCRAd platform into first-in-human cancer clinical trials.
  • Paul G Higham, CEO of Valo Tx, said, "Despite the tremendous progress that has been made, there is still huge potential for immuno-oncology to further improve outcomes for patients.
  • Valo Therapeutics (Helsinki and Oxford) is animmuno-oncology company that is developing tumor antigen-coated oncolytic viruses as anti-cancer therapeutics stimulating specific anti-tumor T-cell responses.
  • Paul G Higham is a healthcare industry veteran with extensive leadership experience in large pharmaceutical and biotech companies.

BioNTech Publishes Data from mRNA-based BNT111 FixVac Melanoma Trial in Nature

Retrieved on: 
Thursday, July 30, 2020
Vaccination, Medicine, Medical specialties, Health, Cancer vaccine, Melanoma, Vaccine, Experimental cancer treatments

MAINZ, Germany, July 30, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ: BNTX, BioNTech or the Company), announced today the publication of interim Phase 1 data for the Companys FixVac cancer vaccine program BNT111 in the journal Nature.

Key Points: 
  • MAINZ, Germany, July 30, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ: BNTX, BioNTech or the Company), announced today the publication of interim Phase 1 data for the Companys FixVac cancer vaccine program BNT111 in the journal Nature.
  • The Lipo-MERIT trial is a multicenter, open-label, dose-escalation Phase 1 trial ( NCT02410733 ) to evaluate safety and tolerability of vaccinated patients with stage IIIB-C and stage IV melanoma.
  • The publication titled An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma summarizes the findings of an exploratory interim analysis (data extraction date July 29, 2019).
  • Safety assessment was performed in 89 advanced melanoma patients treated with intravenously delivered repeated doses of mRNA-based cancer vaccine BNT111 ranging from 7.2g to 400g.

Replimune Appoints Andrea Pirzkall, M.D. as Chief Medical Officer

Retrieved on: 
Wednesday, July 22, 2020
Oncolytic virus, Sparke, Experimental cancer treatments, Chief Medical Officer, Biotechnology, Virotherapy, Adenoviridae

as Replimunes Chief Medical Officer effective August 31st, 2020.

Key Points: 
  • as Replimunes Chief Medical Officer effective August 31st, 2020.
  • We are very excited to have Andrea join the Replimune team as we aggressively advance our pipeline, said Philip Astley-Sparke, Chief Executive Officer of Replimune.
  • Dr. Pirzkall commented, It is a privilege to be joining Replimune at this very exciting period in the Companys growth.
  • As Chief Medical Officer, Dr. Pirzkall will lead clinical development of Replimunes pipeline of next-generation oncolytic immuno-gene therapies for the treatment of cancer.

Oncorus Announces Clinical Trial Collaboration with Merck to Evaluate the Combination of Oncorus’ ONCR-177 with Merck’s KEYTRUDA® (pembrolizumab)...

Retrieved on: 
Thursday, July 16, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Virotherapy, Medicine, Oncolytic virus, Clinical medicine, Herpes simplex virus, Immunotherapy, Contents, Experimental cancer treatments, Cancer immunotherapy, Biotechnology, ONCR-177, Oncorus

ONCR-177, Oncorus lead product candidate, is an intratumorally administered oncolytic Herpes Simplex Virus (oHSV) viral immunotherapy being developed for the treatment of multiple solid tumor indications.

Key Points: 
  • ONCR-177, Oncorus lead product candidate, is an intratumorally administered oncolytic Herpes Simplex Virus (oHSV) viral immunotherapy being developed for the treatment of multiple solid tumor indications.
  • We are pleased to enter into this clinical collaboration with Merck, as we believe the mechanisms of ONCR-177 and KEYTRUDA are highly complementary, said Theodore (Ted) A. Ashburn, M.D., Ph.D., President and Chief Executive Officer of Oncorus.
  • Combining these two approaches has the potential to enhance antitumor immunity, and form immunologic memory against tumors.
  • At Oncorus, we are focused on driving innovation to deliver next-generation viral immunotherapies to transform outcomes for cancer patients.

Transgene’s and BioInvent’s BT-001 Achieves Outstanding Tumor Cure Rates in Preclinical Models

Retrieved on: 
Monday, June 22, 2020
Other Health, Research, Pharmaceutical, Oncology, Infectious diseases, Hospitals, Genetics, Clinical trials, Science, Biotechnology, Other Science, Health, Medical specialties, Immunology, Medicine, CTLA-4, Monoclonal antibodies, Immune system, Experimental cancer treatments, Virotherapy, Cancer immunotherapy, Programmed cell death protein 1

It has been designed to combine the killing of cancer cells (oncolysis), and the production of the anti-CTLA4 antibody and GM-CSF directly in the tumor site, while also generating an immune response against tumor cells.

Key Points: 
  • It has been designed to combine the killing of cancer cells (oncolysis), and the production of the anti-CTLA4 antibody and GM-CSF directly in the tumor site, while also generating an immune response against tumor cells.
  • These data indicate that BT-001 has the potential to make a significant difference in the treatment of solid tumors and as such, underpin the effectiveness of both Transgenes and BioInvents technology platforms.
  • Main points from the presentation included:
    The anti-CTLA4 antibody and GM-CSF accumulate in tumors with low systemic exposure.
  • Two preclinical programs in solid tumors are expected to enter clinical trials by the end of 2020.

Calidi Biotherapeutics Announces Two Abstracts Accepted for Presentation at AACR 2020 Virtual Annual Meeting II

Retrieved on: 
Monday, June 22, 2020
Science, Stem cells, Biotechnology, Research, Oncology, Health, Infectious diseases, Clinical trials, Oncolytic virus, Cancer immunotherapy, Virotherapy, Experimental cancer treatments, Medicine, Clinical medicine, Biotechnology, Medical specialties, Adenoviridae, Akseli Hemminki, Calidi Biotherapeutics, the AACR Virtual Annual Meetings

AACR presentation details are as follows:

Key Points: 
  • AACR presentation details are as follows:
    Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology that is revolutionizing the effective delivery of oncolytic viruses for targeted therapy against difficult-to-treat cancers.
  • Calidi Biotherapeutics is advancing a potent allogeneic stem cell and oncolytic virus combination for use in multiple oncology indications.
  • The 2020 AACR Virtual Annual Meeting I took place from April 27 to April 28, 2020.
  • Calidi Biotherapeutics does not make any representation or warranty, express or implied, as to the completeness or updated status of such statements.

Replimune to Participate at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference

Retrieved on: 
Wednesday, June 17, 2020
Medicine, Clinical medicine, Medical specialties, Cancer immunotherapy, Oncolytic virus, Checkpoint inhibitor, Biotechnology, Experimental cancer treatments

WOBURN, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present in a fireside chat and host investor meetings at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference being held virtually on June 23, 2020 at 9:30 a.m.

Key Points: 
  • WOBURN, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present in a fireside chat and host investor meetings at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference being held virtually on June 23, 2020 at 9:30 a.m.
  • Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer.
  • The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment.
  • Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action.For more information, please visit www.replimune.com .